Comments on: Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

Comments on: Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study - kaiyun体育全站入口 //www.yitiaoweiba.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%a6%96%e6%ac%a1%e5%85%ac%e5%b8%83%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9b%b4%e6%89%8b%e6%9c%af%e6%9c%9f%e6%b2%bb%e7%96%97%e9%9d%9e%e5%b0%8f/ 创新疗法的发现、开发和商业化的生物制药公司。 Thu, 04 May 2023 10:41:04 +0000 hourly 1 https://wordpress.org/?v=6.7.2